M
Michel Gelbcke
Researcher at Université libre de Bruxelles
Publications - 75
Citations - 1030
Michel Gelbcke is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Myeloperoxidase & Nuclear magnetic resonance spectroscopy. The author has an hindex of 18, co-authored 72 publications receiving 895 citations. Previous affiliations of Michel Gelbcke include VU University Amsterdam & UCB.
Papers
More filters
Journal ArticleDOI
New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation.
Rémi Rosiere,Matthias Van Woensel,Michel Gelbcke,Véronique Mathieu,Julien Hecq,Thomas Mathivet,Marjorie Vermeersch,Pierre Van Antwerpen,Karim Amighi,Nathalie Wauthoz +9 more
TL;DR: The preclinical findings demonstrated the positive impact of the coated SLN on the delivery of paclitaxel by inhalation and demonstrated that FR was involved in these improvements, especially in M109-HiFR cells.
Journal ArticleDOI
DYRK1A kinase inhibitors with emphasis on cancer.
Alexandra Ionescu,François Dufrasne,Michel Gelbcke,Ivan Jabin,Robert Kiss,Delphine Lamoral-Theys +5 more
TL;DR: The present review discusses the available molecules known to interfere with DYRK1A activity and the implications of DYRk1A in cancer and other diseases and serves as a rational analysis for researchers who aim to improve the anti-DYRK 1A activity of currently available compounds.
Journal ArticleDOI
1-Synthesis of octa- and nonahelicenes. 2-New syntheses of hexa- and heptahelicenes. 3-Optical rotation and O.R.D. of heptahelicene.
Journal ArticleDOI
A survey of the mechanisms of action of anticancer transition metal complexes.
TL;DR: This review focuses on recent findings about the anticancer mechanism of action of metal complexes and how the ligands can be used to tune their pharmacological and physicochemical properties.
Journal ArticleDOI
Structure-based design, synthesis, and pharmacological evaluation of 3-(aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors.
Jalal Soubhye,Martine Prévost,Pierre Van Antwerpen,Karim Zouaoui Boudjeltia,Alexandre Rousseau,Paul G. Furtmüller,Christian Obinger,Michel Vanhaeverbeek,Jean Ducobu,Jean Neve,Michel Gelbcke,François Dufrasne +11 more
TL;DR: A series of 3-(aminoalkyl)-5-fluoroindole analogues was designed and synthesized by exploiting the structure-based docking of 5-fluorotryptamine, a known MPO inhibitor, and the mode of binding of these analogues and the mechanism of inhibition is discussed with respect to the structure of MPO and its halogenation and peroxidase cycles.